• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Rani Therapeutics Holdings Inc.

    8/14/25 9:02:07 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RANI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    RANI THERAPEUTICS HOLDINGS-A

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    502074503

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    502074503


    1Names of Reporting Persons

    Armistice Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,312,354.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,312,354.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,312,354.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.79 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    502074503


    1Names of Reporting Persons

    Steven Boyd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,312,354.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,312,354.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,312,354.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.79 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    RANI THERAPEUTICS HOLDINGS-A
    (b)Address of issuer's principal executive offices:

    2051 RINGWOOD AVENUE, SAN JOSE, CA, 95131
    Item 2. 
    (a)Name of person filing:

    Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
    (b)Address or principal business office or, if none, residence:

    Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
    (c)Citizenship:

    Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    502074503
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4,312,354
    (b)Percent of class:

    8.79  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    4,312,354

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    4,312,354 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Armistice Capital, LLC
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd - Managing Member
    Date:08/14/2025
     
    Steven Boyd
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd
    Date:08/14/2025
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

    Get the next $RANI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RANI

    DatePrice TargetRatingAnalyst
    8/2/2024$17.00Outperform
    Oppenheimer
    6/14/2024$15.00Buy
    Maxim Group
    6/13/2024$10.00Buy
    Rodman & Renshaw
    4/17/2023$24.00Buy
    BTIG Research
    10/11/2022$15.00Buy
    UBS
    7/27/2022$22.00Buy
    H.C. Wainwright
    6/13/2022$28.00Outperform
    Wedbush
    8/25/2021$24.00Buy
    BTIG
    More analyst ratings

    $RANI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Business Officer Mckinley Kate

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    8/5/25 4:12:53 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Nanavaty Maulik

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    5/30/25 5:59:04 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Imran Mir A

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    5/30/25 5:57:02 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Rani Therapeutics with a new price target

    Oppenheimer initiated coverage of Rani Therapeutics with a rating of Outperform and set a new price target of $17.00

    8/2/24 7:39:43 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Rani Therapeutics with a new price target

    Maxim Group initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $15.00

    6/14/24 9:10:16 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Rani Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $10.00

    6/13/24 7:14:35 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

    – Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 – – Phase 1 study for RT-114 for the treatment of obesity expected to initiate in the second half of 2025 – – Announced a warrant inducement transaction with an existing investor with gross proceeds of $4.3 million – – Announced pricing of $3.0 million registered direct offering – SAN JOSE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics"

    8/7/25 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

    SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,354,000 shares of Rani Therapeutics' Class A common stock at a purchase price of $0.40 per share and pre-funded warrants to purchase 3,146,000 shares of Class A common stock at a purchase price of $0.3999 in a registered direct offering. The exercise price of each pre-funded warrant is $0.0001 per share of Class A common stock.

    7/15/25 9:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

    SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society's Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Details of the presentations are as follows: Abstract Title: Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines Session Type: Poster Presentation Session Title: Adipos

    7/14/25 5:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    SEC Filings

    View All

    SEC Form EFFECT filed by Rani Therapeutics Holdings Inc.

    EFFECT - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)

    8/15/25 12:15:28 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Rani Therapeutics Holdings Inc.

    SCHEDULE 13G - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    8/14/25 9:02:07 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Rani Therapeutics Holdings Inc.

    S-3 - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)

    8/8/25 4:06:43 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Mckinley Kate bought $29,993 worth of shares (17,960 units at $1.67) (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    12/16/24 6:00:49 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Imran Talat bought $19,974 worth of shares (10,296 units at $1.94), increasing direct ownership by 2% to 494,751 units (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    12/10/24 1:12:17 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    South Cone Investments Limited Partnership bought $10,582,982 worth of shares (5,265,165 units at $2.01) (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    12/8/23 4:27:22 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Leadership Updates

    Live Leadership Updates

    View All

    Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

    - Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association's Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings,

    8/11/23 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

    SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has appointed Kate McKinley as its Chief Business Officer. "Kate is a seasoned industry leader, and we are thrilled to welcome her to Rani's executive team," said Talat Imran, Chief Executive Officer of Rani. "Kate's expertise in corporate strategy, business development and commercialization will further strengthen our leadership team and partnering efforts, while positioning the Company for its next stage of growth. Kate will have a vital role

    5/24/23 8:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update

    - Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg – - Strengthened Board with the appointment of Lisa Rometty - SAN JOSE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. "We started the year off strong, having unveiled the high-capacity RaniPill HC, advanced RT-102 into the clinic for a Phase 1 trial in o

    5/11/22 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Financials

    Live finance-specific insights

    View All

    Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

    - Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 - - Conference call today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeut

    3/31/25 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

    SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 31, 2025. Individuals interested in listenin

    3/25/25 6:00:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

    ~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ SAN JOSE, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani")(NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and

    6/24/24 7:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rani Therapeutics Holdings Inc.

    SC 13G - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    11/14/24 3:36:16 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Rani Therapeutics Holdings Inc.

    SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    10/17/24 4:32:40 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Rani Therapeutics Holdings Inc. (Amendment)

    SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    12/8/23 4:31:53 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care